Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Broad Center for Mendelian Genomics, |
RCV001724845 | SCV001950427 | likely pathogenic | Retinitis pigmentosa | 2021-04-01 | criteria provided, single submitter | curation | The p.Val3131GlyfsTer14 variant in USH2A was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab (https://oculargenomics.meei.harvard.edu/labs/pierce-lab/lab-members/). Through a review of available evidence we were able to apply the following criteria: PVS1, PM2. Based on this evidence we have classified this variant as Likely Pathogenic. If you have any questions about the classification please reach out to the Pierce Lab. |
Labcorp Genetics |
RCV002539741 | SCV002952313 | pathogenic | not provided | 2022-05-13 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with USH2A-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val3131Glyfs*14) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). ClinVar contains an entry for this variant (Variation ID: 1297141). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV003451859 | SCV004182701 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003451859 | SCV004206409 | likely pathogenic | Retinitis pigmentosa 39 | 2022-06-27 | criteria provided, single submitter | clinical testing |